MALDI-TOF Mass Spectrometry Distinguishes Daratumumab from M-proteins

Overview

Journal Clin Chim Acta

Specialty Biochemistry

Date 2019 Feb 22

PMID 30790545

Citations 19

Authors

Lauren M Moore

Sun Cho

Katie L Thoren

Affiliations

Soon will be listed here.

Abstract

Background: Daratumumab, a therapeutic IgG kappa monoclonal antibody, can cause a false positive interference on electrophoretic assays that are routinely used to monitor patients with monoclonal gammopathies. In this study, we evaluate the ability of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) to distinguish daratumumab from disease-related IgG kappa monoclonal proteins (M-protein).

Methods: Waste clinical samples from 31 patients who were receiving daratumumab and had a history of IgG kappa monoclonal gammopathy were collected. Immunoglobulins were purified from serum and analyzed by MALDI-TOF MS. Mass spectra were assessed for the presence of distinct monoclonal proteins. For samples in which only one monoclonal peak was identified near the expected m/z of daratumumab, the Hydrashift 2/4 Daratumumab Assay was used to confirm the presence of an M-protein.

Results: Using MALDI-TOF MS, daratumumab could be distinguished from M-proteins in 26 out of 31 samples (84%). Results from 2 samples were inconclusive since the M-protein was not detected by the Hydrashift assay and may also be undetectable by MALDI-TOF MS. Comparatively, daratumumab was distinguishable from M-proteins in 14 out of 31 samples (45%) by immunofixation.

Conclusions: MALDI-TOF MS offers greater specificity compared to immunofixation for distinguishing daratumumab from M-proteins.

Citing Articles

Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).

Fan H, Wang B, Shi L, Pan N, Yan W, Xu J Clin Cancer Res. 2024; 30(6):1131-1142.

PMID: 38170583 PMC: 10940853. DOI: 10.1158/1078-0432.CCR-23-2767.

The burden of myeloma: novel approaches to disease assessment.

Ho M, Kourelis T Hematology Am Soc Hematol Educ Program. 2022; 2022(1):356-362.

PMID: 36485143 PMC: 9820131. DOI: 10.1182/hematology.2022000348.

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma.

Martin T, Mikhael J, Hajek R, Kim K, Suzuki K, Hulin C Blood Adv. 2022; 6(15):4506-4515.

PMID: 35594559 PMC: 9636327. DOI: 10.1182/bloodadvances.2021006713.

Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).

Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace P, Dasari S Blood Cancer J. 2022; 12(2):27.

PMID: 35145071 PMC: 8831597. DOI: 10.1038/s41408-022-00624-6.

Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.

Abdallah N, Murray D, Dispenzieri A, Kapoor P, Gertz M, Lacy M Leukemia. 2022; 36(5):1426-1428.

PMID: 35091659 PMC: 9061287. DOI: 10.1038/s41375-021-01501-0.

References

Milani P, Murray D, Barnidge D, Kohlhagen M, Mills J, Merlini G . The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic. Am J Hematol. 2017; 92(8):772-779. DOI: 10.1002/ajh.24772. View

Mateos M, Dimopoulos M, Cavo M, Suzuki K, Jakubowiak A, Knop S . Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017; 378(6):518-528. DOI: 10.1056/NEJMoa1714678. View

Willrich M, Ladwig P, Andreguetto B, Barnidge D, Murray D, Katzmann J . Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clin Chem Lab Med. 2016; 54(6):1085-93. DOI: 10.1515/cclm-2015-1023. View

Murata K, McCash S, Carroll B, Lesokhin A, Hassoun H, Lendvai N . Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clin Biochem. 2016; 51:66-71. PMC: 5360528. DOI: 10.1016/j.clinbiochem.2016.09.015. View

Mills J, Murray D . Identification of Friend or Foe: The Laboratory Challenge of Differentiating M-Proteins from Monoclonal Antibody Therapies. J Appl Lab Med. 2021; 1(4):421-431. DOI: 10.1373/jalm.2016.020784. View

Touzeau C, Moreau P . Daratumumab for the treatment of multiple myeloma. Expert Opin Biol Ther. 2017; 17(7):887-893. DOI: 10.1080/14712598.2017.1322578. View

Ruinemans-Koerts J, Verkroost C, Schmidt-Hieltjes Y, Wiegers C, Curvers J, Thelen M . Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins. Clin Chem Lab Med. 2014; 52(11):e235-7. DOI: 10.1515/cclm-2013-0898. View

McCudden C, Voorhees P, Hainsworth S, Whinna H, Chapman J, Hammett-Stabler C . Interference of monoclonal antibody therapies with serum protein electrophoresis tests. Clin Chem. 2010; 56(12):1897-9. DOI: 10.1373/clinchem.2010.152116. View

McCudden C, Jacobs J, Keren D, Caillon H, Dejoie T, Andersen K . Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences. Clin Biochem. 2017; 51:72-79. DOI: 10.1016/j.clinbiochem.2017.08.013. View

10.

Mills J, Kohlhagen M, Willrich M, Kourelis T, Dispenzieri A, Murray D . A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood. 2018; 132(6):670-672. DOI: 10.1182/blood-2018-05-848986. View

11.

Mills J, Kohlhagen M, Dasari S, Vanderboom P, Kyle R, Katzmann J . Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clin Chem. 2016; 62(10):1334-44. DOI: 10.1373/clinchem.2015.253740. View

12.

Thoren K, Pianko M, Maakaroun Y, Landgren C, Ramanathan L . Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay. J Appl Lab Med. 2019; 3(5):857-863. PMC: 7484995. DOI: 10.1373/jalm.2018.026476. View